VA Will Cover Alzheimer’s Disease Drug Lecanemab, Provided A Detailed Set Of Inclusion And Exclusion Criteria Are Met

On Monday, March 13th, the VA announced it is covering the Alzheimer’s drug lecanemab (Leqembi), with conditions of reimbursement - inclusion and exclusion criteria - that are consistent with but also go well beyond the FDA label.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive